Background: Vitamin D deficiency is more prevalent among SLE patients than the general population. Over the past decade, many studies across the globe have been carried out to investigate the role of vitamin D in SLE from various clinical angles. Therefore, the aim of this systematic review is to summarise and evaluate the evidence from the published literature; focusing on the clinical significance of vitamin D in SLE.
Introduction
The link between vitamin D and systemic lupus erythematosus (SLE) was first described in 1995 [1] . The discovery of vitamin D receptor expression by cells of the immune system has spurred more research on the immunomodulatory properties of vitamin D over the past decade. Both the innate and adaptive immune systems have a wide array of cells such as macrophages, dendritic cells, T cells, and B cells which express vitamin D receptors that may respond to the biologically active form of vitamin D (1,25-dihydroxyvitamin D) [2] . Several studies across the globe have reported that vitamin D deficiency is more prevalent among SLE patients than the general population [3] . A possible explanation for this is the sun avoidance by SLE patients, which is an established trigger of lupus flares.
To date, there are over a hundred studies on SLE and vitamin D. The investigators of these studies have tried to establish the prevalence of vitamin D deficiency and its significance in various clinical aspects such as disease activity, disease damage and laboratory parameters. A question which is yet to be answered is whether or not vitamin D deficiency truly alters the course and prognosis of SLE. The answer to this question has important clinical implications, as it may offer potential therapeutic possibilities with vitamin D supplementation. Therefore, the aim of this systematic review is to summarise and evaluate the evidence from published literature focusing on the clinical significance of vitamin D in SLE.
Methodology

Search Strategy
We used the terms ''lupus'', ''systemic lupus erythematosus'', ''SLE'', ''vitamin D'' and 'SLE and vitamin D'' to search the following databases: MEDLINE, Scopus, Web of Knowledge and CINAHL. Furthermore, the references of all retrieved articles were reviewed for relevant citations.
Inclusion Criteria
All adult human cohort and case-control studies written in English, which investigated the role and effects of vitamin D in SLE published between the years 2000 and 2012 were included.
Exclusion Criteria
Studies in other languages apart from English, case reports, case series, animal studies letters to the editor and review articles were excluded. Regarding the justification for excluding paediatric studies; apart from the age factor, paediatric SLE runs a more aggressive clinical course than adult SLE with higher rates of organ involvement and the disease tends to be more severe at presentation [4, 5] . Besides, studies on vitamin D receptor gene polymorphisms were not selected. Most of the aforementioned studies lacked emphasis on and were not powered to investigate the correlation between measured vitamin D levels (25[OH]D) and its clinical significance [6, 7, 8] . Stringent selection criteria were applied in order to achieve a high level of homogeneity in the studies included in this systematic review.
Screening of Articles for Eligibility
Retrieved articles were screened for eligibility based on titles and abstracts and were subsequently classified as 'include', 'possible' and 'exclude' categories. The 'include' and 'possible' categories comprised studies reporting (1) measured vitamin D levels and/or vitamin D supplementation, and (2) disease activity, disease damage, laboratory parameters and/or organ involvement in SLE. In the 'possible' category, there were uncertainties concerning the study design, sample population or objectives. For articles falling into the 'include' and 'possible' categories, where available, the full texts were obtained and assessed. Both authors participated in the selection of articles and only articles which were agreed upon by both were finally included in the review. Throughout the selection process, both authors reached consensus in every instance. Figure 1 summarises the algorithm followed in the selection of studies.
Data Extraction
The following data were extracted from the selected studies: study design; country; year; sample size; disease activity and damage scoring systems; organ involvement and findings. The relevant and particularly, significant statistical values were recorded (odds ratios [OR] , p values, rho [r]).
Results
A total of 22 studies met the eligibility criteria. The vast majority of the studies were observational (95.5%) and cross-sectional (90.9%). Eight case-control studies and 14 cohort studies were included. The number of studies originating from each continent is as follows: 8 from America, 6 from Europe, 6 from Asia, 1 from Australia and 1 from Africa. Study sample sizes varied from 37 to 378 subjects. All studies used 25-hydroxyvitamin D to determine the vitamin D level. Table 1 highlights the findings of the selected studies.
Vitamin D and its Association with SLE Disease Activity and Damage
The disease activity was assessed in most studies with validated scoring systems such as SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), BILAG (British Isles Lupus Activity Group), and ECLAM (European Consensus of Lupus Activity Measurement). In 6 of the studies, the disease damage was investigated with the Systemic Lupus International Collaborating Clinics Damage Index (SDI) [9, 10, 11, 12, 13, 14] . Across the studies, the correlation between vitamin D levels and SLE disease activity has been rather inconsistent. Out of the 15 studies which looked into this aspect, two third of the studies (10/15) reported a significant inverse association between vitamin D and the measured disease activity [10, 14, 15, 16, 17, 18, 19, 20, 21, 22] . There were no significant methodological variations between the 10 studies showing an inverse relationship between vitamin D and the disease activity and the 5 studies that did not show such relationship. The outcome measurement used in all the 5 studies was SLEDAI [9, 11, 12, 13, 23] . Similarly, 90% (9/10) of the studies which demonstrated a significant inverse relationship used SLEDAI. Of note, 3 out of the 5 negative studies in this regard were Spanish [9, 11, 13] , and 2 of them were by the same authors [9, 11] .The damage scores, on the other hand, in 5 out of 6 studies failed to demonstrate a significant association with vitamin D levels [9, 11, 12, 13, 14] .
In clinical practice, anti double stranded (ds) DNA and complement levels are simple, yet useful tools to monitor SLE disease activity. High titres of antidsDNA and low complement levels are associated with lupus flares [24] .The majority of studies showed a significant inverse relationship between vitamin D levels and the former [14, 18, 19] and a direct relationship with the latter [12, 19] . Along this line, Ritterhouse et al. [25] found that that vitamin D deficiency was associated with significantly higher B cell activation and interferon alpha activity. Bogaczewicz et al. [26] had conflicting results in this regard with their finding of vitamin D deficiency being associated with lower concentrations of interleukin 23.
Vitamin D and VAS (Visual Analogue Score)
The VAS was used to evaluate the patients' global assessment [9, 20, 27] and level of fatigue [11, 23, 28] . The findings of these studies showed no consistent pattern with respect to the relationship between the VAS and vitamin D levels. Only half of the studies found significant inverse correlation between these parameters [11, 20, 27] . The remaining studies found no significant association.
Vitamin D and Cardiovascular Risk Factors
There were 4 studies which investigated the relationship between vitamin D deficiency and cardiovascular risk factors such as hypercholesterolaemia, insulin resistance/diabetes mellitus and hypertension [10, 20, 22, 29] . Wu et al. [10] found a significant association with insulin resistance which was consistent with the results of the study by Reynolds et al. [22] . Mok et al. [20] demonstrated a higher total/high density lipoprotein (HDL) cholesterol ratio in vitamin D deficient subjects supporting the findings of Wu et al. [10] of higher low density lipoprotein (LDL) cholesterol with lower vitamin D levels. Reynolds et al. [22] and Ravenell et al. [29] had conflicting results on the correlation with carotid plaque. Ravenell et al. [29] discovered that vitamin D levels inversely correlated with age-adjusted total plaque area while Reynolds et al. [22] found the opposite. The latter, however demonstrated a significant increase in aortic stiffness with reducing levels of vitamin D.
Discussion
The results of this systematic review indicate that there is substantial evidence to convince us of the association between vitamin D levels and SLE disease activity. However, one may argue that a few of the studies refute this finding and cast doubts on the aforementioned link. It is noteworthy that the 3 largest studies with sample sizes of 378,290 and 181 subjects, revealed strong inverse correlations between vitamin D levels and SLEDAI scores with p values of 0.018,,0.001 and 0.001, respectively [10, 14, 16] . Mok et al. [14] concluded that vitamin D deficiency is a marker of SLE disease activity with comparable specificity to anti-C1q. The conflicting results of the few studies could be due to the diverse study populations, methodological variations and the power of several studies [11, 13, 23] was probably too low to achieve statistical significance. While the results of these observational studies are helpful for generating hypotheses concerning the effects of vitamin D on the clinical course of SLE, it is unwise to make causal inferences from these studies.
Lupus disease activity predicts the risk of subsequent organ damage [30] . Intriguingly, the majority of studies consistently demonstrated that vitamin D level is not associated with organ damage [9, 11, 12, 13, 14] . The authors are unable to provide any valid evidence-based explanation for this observation. This finding limits or perhaps, deters the use of vitamin D levels as a prognostication tool. Kamen et al. (4) and Bogaczewicz et al. (22) found an association between vitamin D levels and renal disease. Similarly, Reynolds et al. (24) and Ravenell et al. (25) pointed out a significant relationship with the cardiovascular system. These findings need to be tested rigorously by larger prospective studies to make firm conclusions. As these studies are too few in number, there is still profound lack of evidence to support the role of vitamin D in the management of the individual organ system. Nevertheless, this is an area worthy of further research due to the biologic plausibility of a link between vitamin D deficiency and especially, cardiovascular and renal disease in SLE.
Our systematic review has limitations. We did not include articles in other languages which may have had valuable information or additional evidence related to this topic. It is reasonable to assume that some studies with negative or null results were simply not published; a well recognised publication bias. The cross sectional study design used in the majority of these studies does not give us a clear picture as to whether vitamin D deficiency confers a poorer outcome of SLE in the long term. Future research on vitamin D in SLE will hopefully address more practical concerns and provide answers to the following questions : the most appropriate phase of SLE to assess vitamin D (ie, at the time of diagnosis or while in remission); the cutoff value of 'normal' versus 'insufficient' vitamin D levels in lupus patients as compared to the general population; potential confounding factors such as medications, age, body size, geographic location, ethnicity, sun protective behaviours; and genetic variation in the metabolism of vitamin D. Much emphasis has been placed on vitamin D in SLE in recent years. Apart from its significant association with disease activity, based on the evidence highlighted in this systematic review, it is premature and would be fallacious to make any definitive claims for or against the role of vitamin D in other clinical aspects.
